查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1737105

全球重度忧郁症(MDD) 市场规模（按产品、应用和地区划分）- 预测

Global Major Depressive Disorder (MDD) Market Size By Product, By Application, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

重度忧郁症（MDD）市场规模及预测

预计 2024 年全球重度忧郁症(MDD) 市场规模将达到 57 亿美元，到 2032 年将达到 106 亿美元，预测期内（2026-2032 年）的复合年增长率为 8.4%。

推动全球重度忧郁症（MDD）市场发展的因素

重度忧郁症(MDD) 市场驱动因素可能受到多种因素的影响。这些因素包括：

重度忧郁症（MDD）的盛行率和发生率决定了医疗保健和处方药的需求。由于MDD是一种全球流行的精神疾病，其盛行率直接影响市场规模。

研发：研发促进新药、治疗方法和新治疗方式的开发，有助于扩大市场。资助MDD治疗研发的製药公司有助于扩大市场。

法规环境：监理、审批和政策变化影响市场动态。监管机构对新药和新适应症的核准会对市场扩张产生重大影响。

技术进步：经颅磁刺激 (TMS) 和氯胺酮输注疗法等治疗方式以及脑部影像技术等诊断程序的创新将透过开闢管理 MDD 的新途径来影响市场。

意识和教育工作：透过宣传和教育宣传活动提高大众对重度忧郁症（MDD）等心理健康问题的认识，可以鼓励早期诊断和寻求治疗的行为，进而影响市场。

医疗保健提供者的可及性、报销指南以及MDD治疗的保险覆盖范围都会影响市场成长。优惠的报销政策和完善的医疗基础设施可以提升市场潜力。

人口趋势：MDD 的流行以及治疗需求可能会受到人口老化和生活方式改变等因素的影响。

合併症：慢性病和焦虑症是一种经常与重度忧郁症（MDD）同时发生的疾病。某些合併症的盛行率将影响治疗前景和市场动态。

经济因素：保险覆盖范围、医疗费用支出和收入水准等许多经济因素都会影响 MDD 治疗的可近性和可负担性，进而影响市场成长。

患者偏好和治疗结果：市场趋势由患者对心理治疗和药物治疗等特定治疗方式的偏好以及治疗在实现预期结果方面的有效性所驱动。

限制全球重度忧郁症（MDD）市场的因素

有几个因素可能会对重度忧郁症(MDD) 市场造成限制和挑战。这些因素包括：

耻辱和意识：儘管人们努力提高认识，重度忧郁症（MDD）等精神疾病仍然带有耻辱感，这可能会阻止人们接受治疗并限制市场扩张。

监管障碍：针对新药和新疗法的严格指导方针和核准程序可能会阻碍治疗 MDD 的新药的发现和推出，从而减缓市场扩张。

昂贵的药物和心理治疗：MDD 的治疗通常需要药物和心理治疗相结合，这些治疗费用昂贵且并非人人都能接受，这可能会阻碍市场扩张，尤其是在医疗保健和保险覆盖有限的地区。

非专利竞争：学名药抗忧郁症的推出或专利到期可能会导致品牌药价格下降、销售减少，进而影响市场规模。

现有治疗方法疗效有限：儘管治疗重度忧郁症（MDD）的方法多种多样，但并非所有方法都对每个人都有效。随着相关人员和患者不断寻求更有效的治疗方法，这些限制可能会阻碍市场扩张。

共病性与复杂性：重度忧郁症的治疗往往因其他精神和躯体疾病的共病而变得复杂。开发有效的共病治疗方法极具挑战性，这可能会阻碍市场扩张。

研发相关风险：临床试验失败和发现非预期副作用是精神健康领域研发的两大固有风险。这些风险可能抑制新型MDD疗法的资金投入，并阻碍市场扩张。

获得医疗保健服务：获得精神健康服务的不平等，特别是在贫困地区和农村地区，可能会限制 MDD治疗方法的接受度并抑制其发展。

治疗抗性：患有抗治疗性忧郁症的重重度忧郁症忧郁症患者可能对传统疗法无反应。针对该族群的开发新药面临障碍，可能限制市场扩张。

目录

第 1 章全球重度忧郁症(MDD) 市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

4. 全球重度忧郁症（MDD）市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球重度忧郁症（MDD）市场（按产品）

  • 概述
  • 苯二氮平类药物
  • 抗忧郁症
  • SSRI
  • SNRI
  • 其他的

第六章 全球重度忧郁症（MDD）市场（按应用）

  • 概述
  • 诊所
  • 医院
  • 其他的

第七章全球重度忧郁症（MDD）市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

8. 全球重度忧郁症（MDD）市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • Bristol-Myers Squibb
  • Pfizer
  • H. Lundbeck
  • GlaxoSmithKline
  • Sanofi-Aventis
  • Merck
  • Forest Laboratories
  • AstraZeneca
  • Johnson & Johnson
  • Eli Lily

第十章 附录

  • 相关调查
简介目录
Product Code: 50843

Major Depressive Disorder (MDD) Market Size And Forecast

Major Depressive Disorder (MDD) Market size was valued at USD 5.7 Billion in 2024 and is projected to reach USD 10.6 Billion by 2032, growing at a CAGR of 8.4 % during the forecast period 2026-2032.

Major Depressive Disorder (MDD) Market is estimated to grow at a CAGR of 8.4% & reach US$ 10.6 Bn by the end of 2032

Global Major Depressive Disorder (MDD) Market Drivers

The market drivers for the Major Depressive Disorder (MDD) Market can be influenced by various factors. These may include:

MDD's prevalence and incidence rates are what determine how much demand there is for medical care and prescription drugs. Given that MDD is a prevalent mental health disorder globally, the market size is directly impacted by its prevalence.

Research and Development: New medicines, therapies, and treatment modalities are developed as a result of research advancements, which propel market expansion. Pharmaceutical firms that fund MDD therapy R&D help to expand the market.

Regulatory Environment: Modifications to regulations' rules, clearances, and policies have an impact on the dynamics of the market. The approval of new medications or indications by regulators can have a big impact on market expansion.

Technological Advancements: By opening up new paths for MDD management, technological innovations in therapeutic modalities like transcranial magnetic stimulation (TMS) and ketamine infusion therapy, as well as diagnostic procedures like brain imaging technologies, have an impact on the market.

Initiatives for Awareness and Education: Raising public knowledge of mental health issues, such as Major Depressive Disorder (MDD), via advocacy and educational campaigns, can encourage early diagnosis and treatment-seeking behaviour, which in turn can influence the market.

Access to healthcare providers, reimbursement guidelines, and insurance coverage for MDD therapies all have an impact on market expansion. Expanding market potential can be achieved through favourable reimbursement policies and improvements in the healthcare infrastructure.

Demographic Trends: The prevalence of MDD and, consequently, the need for therapies can be influenced by factors such as ageing populations and shifting lifestyles.

Comorbid ailments: Chronic illnesses and anxiety disorders are two examples of medical ailments that frequently coexist with MDD. The treatment landscape and market dynamics are influenced by the prevalence of certain comorbidities.

Economic Factors: A number of economic factors, including insurance coverage, healthcare spending, and income levels, have an impact on the accessibility and affordability of MDD therapies, which in turn has an impact on market growth.

Patient Preferences and Treatment Outcomes: What drives market trends are patient preferences for particular treatment modalities, such psychotherapy or medication, as well as how well treatments work to achieve desired results.

Global Major Depressive Disorder (MDD) Market Restraints

Several factors can act as restraints or challenges for the Major Depressive Disorder (MDD) Market. These may include:

Stigma and Awareness: Despite initiatives to increase awareness, there is still stigma associated with mental health conditions like Major Depressive Disorder (MDD). This might prevent people from getting treatment, which in turn restricts the expansion of the market.

Regulatory Obstacles: Tight guidelines and rigorous approval procedures for novel medications and treatments can hinder the creation and launch of MDD remedies, which will slow the market's expansion.

Expensive Medication and Therapy: MDD treatment frequently entails a mix of medication and therapy, which can be costly and may not be accessible to all individuals. This may prevent the market from growing, particularly in areas with poor access to or coverage of healthcare.

Generic Competition: The introduction of generic copies of antidepressant treatments and the expiration of patents on those products may result in price erosion and lower sales for branded drugs, which may have an effect on the size of the market as a whole.

Limited Effectiveness of Current Treatments: Although there are a number of MDD treatment choices available, not all individuals will benefit from them, which can cause frustration and necessitate the use of alternative therapies. This restriction may impede market expansion as healthcare practitioners and patients look for more effective therapies.

Comorbidities and Complexity: Treatment for MDD is frequently complicated by the coexistence of other mental health illnesses or physical ailments. It can be difficult to develop treatments that successfully treat certain comorbidities, which could impede market expansion.

Risks associated with R&D: Clinical trial failure and the identification of unanticipated adverse effects are two of the inherent risks associated with research and development in the field of mental health. These dangers may discourage funding for novel MDD treatments, which would hinder market expansion.

Access to Healthcare Services: Inequalities in mental health service accessibility, particularly in underprivileged or rural regions, may restrict the acceptance of MDD therapies and impede their growth.

Resistance to Treatment: Traditional therapy may not work for certain patients with Major Depressive Disorder (MDD) if they are experiencing treatment-resistant depression. There are obstacles in developing new medicines for this demographic, which could limit market expansion.

Global Major Depressive Disorder (MDD) Market Segmentation Analysis

The Global Major Depressive Disorder (MDD) Market is Segmented on the basis of Product, Application, And Geography. Major Depressive Disorder (MDD) Market Segmentation Analysis

Major Depressive Disorder (MDD) Market, By Product

  • Benzodiazepines
  • Antidepressant Drugs
  • SSRIs
  • SNRIs
  • Others

Based on Product, the market is bifurcated into Benzodiazepines, Antidepressant Drugs, SSRIs, SNRIs, and Others. The Antidepressant Drugs segment holds the largest market share during the forecast period. In adults, MDD is common in those who are 25-44 years. Within a complete lifetime, major depression touches 10% - 25% of women and 5% - 12% of men. Thus, increasing population count prone to these diseases is driving the demand for this segment.

Major Depressive Disorder (MDD) Market, By Application

  • Clinics
  • Hospitals
  • Others

Based on Application, the market is bifurcated into Clinics, Hospitals, and Others. The Clinics segment retains the largest market share and is predicted to witness the highest CAGR during the forecast period. People are affected in various ways by major depression. Some people have to feel agitated and irritable, trouble sleeping, and have sudden weight loss. These factors are fueling the demand for this segment during the forecast period.

Major Depressive Disorder (MDD) Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the Global Major Depressive Disorder (MDD) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America holds the largest market share. The expanded awareness about multiple depression conditions in the region. The U.S. represents the biggest market for major depressive disorder (MDD) in North America, accompanied by Canada. In Europe, Germany, France, Italy, and Spain account for a major share of the Major Depressive Disorder (MDD) Market. This market in Asia is anticipated to expand at a notable rate over the forecast years.

Key Players

  • The major players in the Major Depressive Disorder (MDD) Market are:
  • Bristol-Myers Squibb
  • Pfizer
  • H. Lundbeck
  • GlaxoSmithKline
  • Sanofi-Aventis
  • Merck
  • Forest Laboratories
  • AstraZeneca
  • Johnson & Johnson
  • Eli Lily.IBM Corporation
  • Cleo Communications, Inc.
  • Signiant, Inc.
  • Broadcom, Inc.
  • Wipro Limited

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Benzodiazepines
  • 5.3 Antidepressant Drugs
  • 5.4 SSRIs
  • 5.5 SNRIs
  • 5.6 Others

6 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Clinics
  • 6.3 Hospitals
  • 6.4 Others

7 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East & Africa

8 GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Bristol-Myers Squibb
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Pfizer
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 H. Lundbeck
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 GlaxoSmithKline
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Sanofi-Aventis
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Merck
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Forest Laboratories
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 AstraZeneca
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Johnson & Johnson
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Eli Lily
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research